Apyx Medical Study Shows 81.8% Improvement in Cellulite with Avéli and Renuvion Combo
Event summary
- Apyx Medical published clinical data in Aesthetic Surgery Journal Open Forum showing 81.8% of patients improved cellulite appearance using Avéli and Renuvion combo treatment.
- Study involved 22 patients with measurable reductions in dimple volume, surface area, and depth, including complete resolution in select cases.
- Histological analysis showed increased collagen and elastin levels through 180 days post-treatment.
- Barry E. DiBernardo, MD, led the study highlighting the multi-modality approach to address both structural and skin quality components of cellulite and laxity.
The big picture
Apyx Medical's study underscores the growing demand for minimally invasive solutions addressing cellulite and skin laxity, two prevalent aesthetic concerns. The combination of Avéli and Renuvion targets both structural and surface-level causes, positioning Apyx Medical to capture market share in a segment dominated by non-surgical alternatives. The study's positive outcomes could accelerate adoption among plastic surgeons and dermatologists, particularly as patients seek comprehensive, long-lasting solutions.
What we're watching
- Clinical Validation
- How the study results will impact adoption rates of Avéli and Renuvion combo treatments among aesthetic surgeons.
- Market Differentiation
- Whether Apyx Medical can sustain competitive advantage with evidence-based outcomes in the crowded cellulite treatment market.
- Regulatory Approvals
- The pace at which Apyx Medical can secure additional regulatory clearances for expanded indications based on this study.
Related topics